- This event has passed.
13th Biosimilars Congregation
June 11 @ 08:00 - June 12 @ 17:00
The development of the Biosimilars market is growing exponentially with the industry forecast to be worth $25 billion by 2020. The global biosimilar market is estimated to register a CAGR of 39.53% over the forecast period of 2017-2023. The growth in the market may be attributed to the cost-effectiveness of the biosimilars when compared to reference biologics coupled with the patent expiration of the many blockbuster biologic drugs. By 2018, biologics worth more than US$68 billion annual sales will lose patent protection. Due to structural complexity of the biosimilar drugs, multi-layered manufacturing and risk of immunogenicity, separate regulatory pathways have been drafted to introduce them into the market. Increasing investment by the companies for the development of biosimilars will also be the key factor driving the market.
Our 13th Biosimilars Congregation 2019 will provide insight into the current state of play in the EU and stimulate debate, in a multi-stakeholder setting, on the vital role of biosimilar medicines in the sustainability of healthcare systems. Beyond a comprehensive outlook of key European market access policies, our speakers will outline the key recent developments in regulatory science and regulatory policy in the EU and other international jurisdictions. Special emphasis will be placed on strengthening the link between regulators and medical communities as an essential basis for greater understanding and acceptance of biosimilar medicines. This Biosimilars conference will focus on multiple aspects of Biosimilar product development to successfully deliver safe, Biosimilar products to the market place. By attending this conference, you will gain a comprehensive outlook on the key issues surrounding Biosimilars. This event will provide an important platform for Biosimilars stakeholders to discuss and share best practices in furthering Biosimilars development.